Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39444
Title: | Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. | Authors: | Prince H.M.;Grigoriadis G. ;Talaulikar D.;Tam C.S.;Joshua D.;Ho J.P.;Szer J.;Quach H.;Spencer A.;Harrison S.;Mollee P.;Roberts A.W.;Horvath N.;Lee C.;Zannettino A.;Brown R.;Augustson B.;Jaksic W.;Gibson J.;Kalff A.;Johnston A.;Trotman J.;Kalro A.;Ward C. | Monash Health Department(s): | Haematology | Institution: | (Talaulikar) Department of Haematology, Canberra Hospital, Canberra, ACT, Australia (Talaulikar) Australian National University, Canberra, ACT, Australia (Talaulikar, Joshua, Ho, Szer, Quach, Spencer, Harrison, Mollee, Roberts, Horvath, Lee, Zannettino, Brown, Augustson, Jaksic, Gibson, Kalff, Johnston, Kalro, Ward, Prince) Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, VIC, Australia (Tam, Harrison, Prince) Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Tam, Quach) Department of Haematology, St Vincent's Hospital, Melbourne, VIC, Australia (Tam, Szer, Quach, Spencer, Harrison, Roberts, Prince) Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia (Joshua, Ho, Brown, Gibson) Department of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia (Joshua, Ho, Gibson, Ward) Sydney Medical School, University of Sydney, Sydney, NSW, Australia (Szer, Roberts) Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, VIC, Australia (Spencer, Kalff) Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia (Mollee) Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia (Mollee) School of Medicine, University of Queensland, Brisbane, QLD, Australia (Roberts) Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia (Horvath, Lee) Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia (Zannettino) Faculty of Medical Sciences, University of Adelaide, Adelaide, SA, Australia (Augustson) Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia (Jaksic) Department of Haematology, Queen Elizabeth Hospital, Adelaide, SA, Australia (Johnston) Department of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia (Johnston) Faculty of Health, University of Tasmania, Hobart, TAS, Australia (Trotman) Department of Haematology, Concord Hospital, Sydney, NSW, Australia (Kalro) Department of Haematology, Royal Darwin Hospital, Darwin, NT, Australia (Grigoriadis) Department of Haematology, Southern Health, Melbourne, VIC, Australia (Grigoriadis) Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia (Ward) Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia | Issue Date: | 1-Feb-2017 | Copyright year: | 2017 | Publisher: | Blackwell Publishing (E-mail: info@asia.blackpublishing.com.au) | Place of publication: | Australia | Publication information: | Internal Medicine Journal. 47 (1) (pp 35-49), 2017. Date of Publication: 01 Jan 2017. | Journal: | Internal Medicine Journal | Abstract: | Waldenstrom macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.Copyright © 2017 Royal Australasian College of Physicians | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/imj.13311 | Link to associated publication: | Click here for full text options | PubMed URL: | 28076910 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28076910] | ISSN: | 1444-0903 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39444 | Type: | Article | Subjects: | rituximab/dt [Drug Therapy] plasma viscosity amyloidosis article Australia bone marrow cancer chemotherapy cancer prognosis clinical feature clinical practice differential diagnosis electrophoresis human lymphadenopathy peripheral neuropathy *practice guideline priority journal spleen disease stem cell transplantation treatment response *Waldenstroem macroglobulinemia/dt [Drug Therapy] *Waldenstroem macroglobulinemia/th [Therapy] Waldenstroem macroglobulinemia/dt [Drug Therapy] x-ray computed tomography bendamustine/dt [Drug Therapy] bortezomib/dt [Drug Therapy] carfilzomib/dt [Drug Therapy] chlorambucil/dt [Drug Therapy] cyclophosphamide/dt [Drug Therapy] dexamethasone/dt [Drug Therapy] fludarabine/dt [Drug Therapy] ibrutinib/dt [Drug Therapy] immunoglobulin M/ec [Endogenous Compound] myeloid differentiation factor 88/ec [Endogenous Compound] plasma viscosity *practice guideline priority journal spleen disease stem cell transplantation treatment response *Waldenstroem macroglobulinemia / *drug therapy / *therapy Waldenstroem macroglobulinemia / drug therapy x-ray computed tomography cancer chemotherapy Australia Article amyloidosis bone marrow cancer prognosis clinical feature clinical practice differential diagnosis electrophoresis human lymphadenopathy peripheral neuropathy |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.